Sec Form 3 Filing - Ashe Andrew D. @ Verve Therapeutics, Inc. - 2021-06-16

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Ashe Andrew D. 2. Issuer Name and Ticker or Trading Symbol Verve Therapeutics, Inc. [ VERV] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) See Remarks (Last) (First) (Middle) C/O VERVE THERAPEUTICS, INC., 500 TECHNOLOGY SQUARE, SUITE 901 3. Date of Earliest Transaction (MM/DD/YY) 06/16/2021 (Street) CAMBRIDGE, MA02139 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 166,722 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (right to buy) $ 8.24 ( 1 ) 02/11/2031 Common Stock 107,997 D Stock Option (right to buy) $ 2.87 ( 2 ) 09/15/2030 Common Stock 164,113 D Stock Option (right to buy) $ 1.48 ( 3 ) 09/16/2029 Common Stock 60,748 D Stock Option (right to buy) $ 1.39 ( 4 ) 11/07/2028 Common Stock 51,203 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Ashe Andrew D. C/O VERVE THERAPEUTICS, INC. 500 TECHNOLOGY SQUARE, SUITE 901 CAMBRIDGE, MA02139 See Remarks Signatures /s/ Andrew Ashe 06/16/2021 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The option was granted on February 12, 2021 for 107,997 shares. 25% of the shares underlying the option will vest on February 1, 2022, and the remainder are scheduled to vest in equal monthly installments thereafter until February 1, 2025. ( 2 )The option was granted on September 16, 2020 for 164,113 shares. 25% of the shares underlying the option will vest on September 16, 2021, and the remainder are scheduled to vest in equal monthly installments thereafter until September 16, 2024. ( 3 )The remaining shares underlying this option, which was granted on September 17, 2019, vest over 4 years in equal monthly installments through July 26, 2023. ( 4 )The remaining shares underlying this option, which was granted on November 8, 2018, vest in equal monthly installments until August 20, 2022.

Remarks: President, Chief Operating OfficerExhibit Index: 24.1 Power of Attorney

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.